Description

Tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide that activates two incretin receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This listing supplies tirzepatide as a 20mg lyophilized vial for laboratory research.

What is Tirzepatide?

The peptide backbone is based on the native GIP sequence, modified so that it also binds the GLP-1 receptor. A C20 fatty diacid attached through a linker promotes binding to serum albumin, which extends its half-life to roughly five days in clinical pharmacokinetic studies. Tirzepatide has greater affinity for the GIP receptor than for the GLP-1 receptor, a profile often described as “imbalanced” dual agonism.

It is the active ingredient in two FDA-approved medicines: Mounjaro (2022, type 2 diabetes) and Zepbound (2023, chronic weight management). In the phase 3 SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), participants on the highest dose lost an average of 20.9% of body weight over 72 weeks. That makes tirzepatide the usual reference compound when laboratories study newer incretin-based molecules.

Research Applications

GIP and GLP-1 receptor pharmacology and signalling bias
Energy balance and food-intake models
Insulin secretion and glucose homeostasis
Adipose tissue and hepatic lipid metabolism
Comparator studies with semaglutide and the triple agonist retatrutide

Product Specifications

Size: 20mg per vial (other sizes: 5mg, 15mg, 30mg, 50mg, 60mg)
Form: lyophilized powder in a sealed vial
Purity: ≥99% (HPLC), manufactured in the USA
Certificate of Analysis available for each batch
Storage: store lyophilized product at -20°C, protected from light

Further reading: our Retatrutide research guide compares triple and dual incretin agonists.

For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic. Sold to qualified researchers for in-vitro and laboratory research.